Translational research goes both ways: Lessons from clinical studies

Clinical and Experimental Pharmacology and Physiology

Volumn 35, Issue 4, 2008, Pages 526-529

  Funder, John W ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Aldosterone; Blood pressure regulation; Corticosterone; Cortisol; Heart failure; Hypertension; Mineralocorticoid receptor; Receptor evolution; Translational research

Indexed keywords

ALDOSTERONE; ANDROGEN RECEPTOR; EPLERENONE; GLUCOCORTICOID RECEPTOR; GLUTATHIONE DISULFIDE; MINERALOCORTICOID RECEPTOR; PROGESTERONE RECEPTOR; REACTIVE OXYGEN METABOLITE; SODIUM CHLORIDE; WATER;

ALDOSTERONE RELEASE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DOSE TITRATION; ESSENTIAL HYPERTENSION; GENE; GENE MUTATION; HEART FAILURE; HOMEOSTASIS; HUMAN; MEDICAL RESEARCH; META ANALYSIS; POTASSIUM BLOOD LEVEL; S810L MR GENE; SYSTEMATIC REVIEW;

ALDOSTERONE; AMINO ACID SEQUENCE; ANTIHYPERTENSIVE AGENTS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; CORTICOSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENETIC PREDISPOSITION TO DISEASE; HEART FAILURE; HUMANS; HYPERTENSION; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE;

EID: 40149094203     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2008.04910.x     Document Type: Conference Paper

References (13)

1. Levy D, Rocha R, Funder JW. Distinguishing the antihypertensive and electrolyte effects of eplerenone. J. Clin. Endocrinol. Metab. 2004 89 : 2736 40.
2. Arriza JL, Weinberger C, Cerelli G et al. Cloning of human mineralocorticoid receptor complementary DNA: Structural and functional kinship with the glucocorticoid receptor. Science 1987 237 : 268 75.
3. Geller D, Farhi A, Pinkerton N et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000 289 : 119 23.
4. Hu X, Funder JW. The evolution of mineralocorticoid receptors. Mol. Endocrinol. 2006 20 : 1471 8.
5. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New Engl. J. Med. 1999 341 : 709 17.
6. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New Engl. J. Med. 2003 348 : 1309 21.
7. Pitt B, Reichek N, Willenbrock R et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-left ventricular hypertrophy study. Circulation 2003 108 : 1831 8.
8. Funder JW, Pearce P, Smith R, Smith AI. Mineralocorticoid action: Target-tissue specificity is enzyme, not receptor, mediated. Science 1988 242 : 583 5.
9. Edwards CR, Stewart PM, Burt D et al. Localisation of 11 beta-hydroxysteroid dehydrogenase - Tissue specific protector of the mineralocorticoid receptor. Lancet 1988 2 : 986 9.
10. Funder JW, Myles K. Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: In vivo binding studies. Endocrinology 1996 137 : 5264 8.
11. + and NADH allows the transcriptional corepressors carboxyl-terminal binding protein to serve as a metabolic senor. Proc. Natl Acad. Sci. USA 2003 100 : 9202 7.
12. Ward MR, Kanellakis P, Ramsey D, Funder JW, Bobik A. Eplerenone suppresses constrictive remodelling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 2001 104 : 467 72.
13. Reinking J, Lam MM, Pardee K et al. The Drosophila nuclear receptor E75 contains heme and is gas responsive. Cell 2005 122 : 197 207.